In this issue:
Elevated risk of infection with daratumumab
No survival benefit to prolonged lenalidomide maintenance in standardrisk MM
Demographic disparities in the US over the last two decades
Mexican private practice experience of outpatient bispecific administration
LINKER-MM1: linvoseltamab may be suitable for frail patients
Steroid-sparing daratumumab–ixazomib regimen for frail geriatric patients
The Mayo Clinic 2/20/20 model may be best to identify true high-risk SMM
CAR-PRISM: Could cilta-cel be an operational cure for high-risk SMM?
Redefining FHR myeloma in the context of upfront quadruplet regimens
STAT3/5 mutations linked to inferior prognosis
Please login below to download this issue (PDF)